Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Board Nominations at Vermillion and More


Vermillion has nominated Paul Sohmer to stand for election to its board of directors at the company's upcoming board meeting.

Sohmer is CEO of Viracor-IBT Laboratories. He formerly was CEO of Pathway Diagnostics, Orthocon, and Cylex, and he was chairman of Molecular Biometrics. He also was CEO, chairman, and president at TriPath Imaging and Neuromedical Systems.

Quintiles this week named Tom Pike as CEO, replacing company founder Dennis Gillings, who will continue as executive chairman of the company's board of directors.

Pike worked at Accenture until 2010 where he held a number of roles including global chief operating officer for the company's resources operating group. Since leaving Accenture he has been involved in several technology and healthcare startups.

Morphosys has nominated Karin Eastham and Marc Cluzel as members of the company's supervisory board.

Eastham is director of several corporate boards including Illumina, Amylin, Trius Therapeutics, and Geron. Cluzel is the executive vice president of product development at HUYA Bioscience as well as the founder of C&F Consulting.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.